花旗发表研报指，尽管短期面临地区医保基金压力与带量采购扩张带来的挑战，国药控股管理层仍对行业长期发展持积极态度。管理层预期今年下半年起可能出现转折点，因创新药品及医疗器械销售快速增长、专业服务带动市场份额提升，以及去年下半年基数相对较低。该行将2025至27年收入预测分别下调8%、9%及11%，净利润预测下调12%、11%及11%，目标价由23.8港元微降至22.7港元，评级“买入”。
花旗发表研报指，尽管短期面临地区医保基金压力与带量采购扩张带来的挑战，国药控股管理层仍对行业长期发展持积极态度。管理层预期今年下半年起可能出现转折点，因创新药品及医疗器械销售快速增长、专业服务带动市场份额提升，以及去年下半年基数相对较低。该行将2025至27年收入预测分别下调8%、9%及11%，净利润预测下调12%、11%及11%，目标价由23.8港元微降至22.7港元，评级“买入”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.